H U : Notice of Revisions to Consolidated Earnings Forecasts for the 1H and Full-Year of FY Ending March 31,2022

August 10, 2021

For Immediate Release

Company name: H.U. Group Holdings, Inc.

Representative: Shigekazu Takeuchi, Director,

President and Group CEO

Securities code: 4544 First Section,

Tokyo Stock Exchange

Contact: Atsuko Murakami,

Executive Officer and CFO

Telephone No.: [phone]

Notice of Revisions to Consolidated Earnings Forecasts for the

First Six-Month and Full-Year Periods of Fiscal Year Ending March 31, 2022

H.U. Group Holdings, Inc. hereby announces that it has revised its first six-month and full-year consolidated earnings forecasts for the fiscal year ending March 31, 2022, announced on May 14, 2021, in light of its recent business performance. Details are as follows.

1. Revisions to consolidated earnings forecasts

(1) Forecasts for first six months of fiscal year ending March 31, 2022 (April 1, 2021 - September 30, 2021)

										Profit
				Net sales		Operating		Ordinary profit		attributable to		Earnings per		(Reference)
					profit			owners of		share		EBITDA*
				(Million yen)			(Million yen)
					(Million yen)			parent		(Yen)		(Million yen)
										(Million yen)
	Previously announced	121,000	17,000	18,500	12,500	219.19	23,500
	forecast	(A)
	Revised forecast	(B)	128,000	21,500	21,000	13,500	236.73	28,000
	Change	(B - A)	7,000	4,500	2,500	1,000		―	4,500
	Change	(%)	5.8	26.5	13.5	8.0		―	19.1
	(Reference) Results for the
	same period a year ago	98,566	8,146	7,342	5,102	89.52	14,078
	(First six months of fiscal
	year ended March 31, 2021)

(2) Consolidated Earnings Forecasts for the Fiscal Year Ending March 31, 2022 (April 1, 2021 to March 31, 2022)

										Profit
				Net sales		Operating		Ordinary profit		attributable to		Earnings per		(Reference)
					profit			owners of		share		EBITDA*
				(Million yen)			(Million yen)
					(Million yen)			parent		(Yen)		(Million yen)
										(Million yen)
	Previously announced	242,000	25,500	25,500	16,500	289.34	40,500
	forecast	(A)
	Revised forecast	(B)	249,000	30,000	28,000	17,500	306.87	45,000
	Change	(B - A)	7,000	4,500	2,500	1,000		―	4,500
	Change	(%)	2.9	17.6	9.8	6.1		―	11.1
	(Reference) Results for the
	previous fiscal year		223,016	25,392	25,458	17,468	306.38	37,887
	(Fiscal year ended March 31,
2021)
* EBITDA = Operating profit + Depreciation + Amortization of goodwill

2. Reasons for revision

The Company has revised its consolidated earnings forecasts as described above, because both net sales and profits for the first six-month and full-year periods of the fiscal year ending March 31, 2022 are expected to exceed the previous forecasts. This chiefly reflects an increase in the number of commissioned PCR tests and greater-than-expected demand for high-sensitivitiy quantitative antigen test reagents due to the recent increase in the number of COVID-19 infections in Japan, as well as increasing COVID-19 testing demands associated with large-scale events held in Japan over the summer.

3. Dividend Forecast

The cash dividend forecast for the fiscal year under review (annual dividend: 125 yen per share) is unchanged from that announced on May 14, 2021.

The earnings forecasts above have been prepared based on information available as of the date on which this material was announced. Actual results may differ due to a variety of factors going forward.

End